SALT LAKE CITY, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that BioMarin Pharmaceutical Inc. will use Myriad’s BRACAnalysis® test in connection with its pivotal Phase 3 clinical studies for BMN 673. BMN 673 is a novel, orally-active PARP inhibitor designed to induce synthetic lethality in BRCA-deficient cells.
Help employers find you! Check out all the jobs and post your resume.
